120 related articles for article (PubMed ID: 16046313)
1. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals.
Kim SH; Abbasi F; Chu JW; McLaughlin TL; Lamendola C; Polonsky KS; Reaven GM
Diabetes; 2005 Aug; 54(8):2447-52. PubMed ID: 16046313
[TBL] [Abstract][Full Text] [Related]
2. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals.
Jones CN; Pei D; Staris P; Polonsky KS; Chen YD; Reaven GM
J Clin Endocrinol Metab; 1997 Jun; 82(6):1834-8. PubMed ID: 9177392
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the relationship between obesity and hyperinsulinemia: Role of insulin secretion and insulin clearance.
Kim MK; Reaven GM; Kim SH
Obesity (Silver Spring); 2017 Feb; 25(2):378-383. PubMed ID: 28000428
[TBL] [Abstract][Full Text] [Related]
4. What is the effect of rosiglitazone treatment on insulin secretory function in insulin-resistant individuals? It depends on how you measure it.
Abbasi F; Lamendola C; Reaven GM
Metabolism; 2011 Jan; 60(1):57-62. PubMed ID: 20356610
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
[TBL] [Abstract][Full Text] [Related]
6. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.
Hung YJ; Hsieh CH; Pei D; Kuo SW; Lee JT; Wu LY; He CT; Lee CH; Fan SC; Sheu WH
Clin Endocrinol (Oxf); 2005 Jan; 62(1):85-91. PubMed ID: 15638875
[TBL] [Abstract][Full Text] [Related]
8. Adapting to insulin resistance in obesity: role of insulin secretion and clearance.
Jung SH; Jung CH; Reaven GM; Kim SH
Diabetologia; 2018 Mar; 61(3):681-687. PubMed ID: 29196782
[TBL] [Abstract][Full Text] [Related]
9. [Primary study on characteristics of insulin secretion rate, metabolic clearance rate and sensitivity in non-insulin-dependent diabetic subjects from multiplex diabetic pedigrees].
Ran J; Cheng H; Li F
Zhonghua Yi Xue Za Zhi; 2000 Jan; 80(1):38-41. PubMed ID: 11798736
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal changes in pancreatic beta-cell function and metabolic clearance rate of insulin in pregnant women with normal and abnormal glucose tolerance.
Catalano PM; Drago NM; Amini SB
Diabetes Care; 1998 Mar; 21(3):403-8. PubMed ID: 9540023
[TBL] [Abstract][Full Text] [Related]
11. Fat mass largely contributes to insulin mediated glucose uptake in morbidly obese subjects.
Gniuli D; Castagneto-Gissey G; Iaconelli A; Leccesi L; Mingrone G
Int J Obes (Lond); 2010 Dec; 34(12):1726-32. PubMed ID: 20498658
[TBL] [Abstract][Full Text] [Related]
12. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
13. Plasma leptin levels, insulin secretion, clearance and action on glucose metabolism in anorexia nervosa.
Letiexhe MR; Scheen AJ; Lefèbvre PJ
Eat Weight Disord; 1997 Jun; 2(2):79-86. PubMed ID: 14655846
[TBL] [Abstract][Full Text] [Related]
14. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients.
Voytovich MH; Simonsen C; Jenssen T; Hjelmesaeth J; Asberg A; Hartmann A
Nephrol Dial Transplant; 2005 Feb; 20(2):413-8. PubMed ID: 15615809
[TBL] [Abstract][Full Text] [Related]
15. Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.
Abbasi F; Lima NK; Reaven GM
Metabolism; 2009 Mar; 58(3):373-8. PubMed ID: 19217454
[TBL] [Abstract][Full Text] [Related]
16. Development of hyperinsulinemia and insulin resistance during the early stage of weight gain.
Erdmann J; Kallabis B; Oppel U; Sypchenko O; Wagenpfeil S; Schusdziarra V
Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E568-75. PubMed ID: 18171910
[TBL] [Abstract][Full Text] [Related]
17. Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a single-dose hyperglycaemic clamp study.
Farret A; Chevassus H; Roux B; Petit P; Galtier F
Diabetologia; 2007 Jul; 50(7):1384-7. PubMed ID: 17486315
[TBL] [Abstract][Full Text] [Related]
18. Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance.
Scheen AJ; Letiexhe MR; Lefèbvre PJ
Diabet Med; 1995 Nov; 12(11):985-9. PubMed ID: 8582131
[TBL] [Abstract][Full Text] [Related]
19. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
20. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics.
Ghanim H; Dhindsa S; Aljada A; Chaudhuri A; Viswanathan P; Dandona P
J Clin Endocrinol Metab; 2006 Sep; 91(9):3553-8. PubMed ID: 16804037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
